158 related articles for article (PubMed ID: 1394411)
1. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin.
Dougherty KG; Gaos CM; Bush HS; Leachman DR; Ferguson JJ
Cathet Cardiovasc Diagn; 1992 Aug; 26(4):260-3. PubMed ID: 1394411
[TBL] [Abstract][Full Text] [Related]
2. [-Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty-].
Kunert M; Sorgenicht R; Scheuble L; Ketteler T; Lürken E; Meyer I; Müller A; Emmerich K; Gülker H
Z Kardiol; 1996 Feb; 85(2):118-24. PubMed ID: 8650981
[TBL] [Abstract][Full Text] [Related]
3. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
[TBL] [Abstract][Full Text] [Related]
4. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
[TBL] [Abstract][Full Text] [Related]
5. Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time.
Reiner JS; Coyne KS; Lundergan CF; Ross AM
Cathet Cardiovasc Diagn; 1994 May; 32(1):49-52. PubMed ID: 8039220
[TBL] [Abstract][Full Text] [Related]
6. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
[TBL] [Abstract][Full Text] [Related]
7. Bedside coagulometry during intravenous heparin therapy after coronary angioplasty.
Schroeder AP; Knudsen LL; Husted SE; Knudsen L; Ingerslev J
J Thromb Thrombolysis; 2001 Oct; 12(2):157-63. PubMed ID: 11729367
[TBL] [Abstract][Full Text] [Related]
8. Adequate heparinization during PTCA: assessment using activated clotting times.
Ogilby JD; Kopelman HA; Klein LW; Agarwal JB
Cathet Cardiovasc Diagn; 1989 Dec; 18(4):206-9. PubMed ID: 2605621
[TBL] [Abstract][Full Text] [Related]
9. Correlation between activated clotting time and activated partial thromboplastin times.
Smythe MA; Koerber JM; Nowak SN; Mattson JC; Begle RL; Westley SJ; Balasubramaniam M
Ann Pharmacother; 2002 Jan; 36(1):7-11. PubMed ID: 11816262
[TBL] [Abstract][Full Text] [Related]
10. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty.
Wilson JM; Dougherty KG; Ellis KO; Ferguson JJ
Cathet Cardiovasc Diagn; 1995 Jan; 34(1):1-5. PubMed ID: 7728844
[TBL] [Abstract][Full Text] [Related]
11. Heparin monitoring in the coronary care unit after percutaneous transluminal coronary angioplasty.
Varah N; Smith J; Baugh RF
Heart Lung; 1990 May; 19(3):265-70. PubMed ID: 2341265
[TBL] [Abstract][Full Text] [Related]
12. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
[TBL] [Abstract][Full Text] [Related]
13. Monitoring anticoagulation following intracoronary procedures: which method?
Brack MJ; More RS; Forbat LN; Hubner PJ; Gershlick AH
Int J Cardiol; 1994 Jun; 45(2):103-8. PubMed ID: 7960247
[TBL] [Abstract][Full Text] [Related]
14. An ex vivo comparison of partial thromboplastin time and activated clotting time for heparin anticoagulation in an ovine model.
Berk ZBK; Shah A; Sun W; Griffith BP; Wu ZJ
Artif Organs; 2022 Mar; 46(3):501-505. PubMed ID: 34698388
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.
Atallah S; Liebl M; Fitousis K; Bostan F; Masud F
Perfusion; 2014 Sep; 29(5):456-61. PubMed ID: 24570077
[TBL] [Abstract][Full Text] [Related]
16. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory.
Doherty TM; Shavelle RM; French WJ
Catheter Cardiovasc Interv; 2005 Jul; 65(3):330-7. PubMed ID: 15864806
[TBL] [Abstract][Full Text] [Related]
17. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration.
Marmur JD; Anand SX; Bagga RS; Fareed J; Pan CM; Sharma SK; Richard MF
J Am Coll Cardiol; 2003 Feb; 41(3):394-402. PubMed ID: 12575965
[TBL] [Abstract][Full Text] [Related]
18. The use of activated clotting times to monitor heparin therapy during and after interventional procedures.
Bowers J; Ferguson JJ
Clin Cardiol; 1994 Jul; 17(7):357-61. PubMed ID: 8088021
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention.
Tsimikas S; Beyer R; Hassankhani A
J Thromb Thrombolysis; 2001 May; 11(3):217-21. PubMed ID: 11577260
[TBL] [Abstract][Full Text] [Related]
20. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy.
Feindt P; Seyfert UT; Volkmer I; Straub U; Gams E
Thorac Cardiovasc Surg; 1994 Aug; 42(4):218-21. PubMed ID: 7529949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
